• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

There's No Rush to Purchase Regeneron Stock

The charts are not particularly attractive at this point in time.
By BRUCE KAMICH
Mar 24, 2021 | 10:10 AM EDT
Stocks quotes in this article: REGN

In his No-Huddle Offense segment of Tuesday's Mad Money, Jim Cramer sounded off on our past year trying to deal with COVID. He said while we're finally starting to do a better job getting people vaccinated, just about all of the other rules, regulations and plans surrounding this pandemic have been downright nonsensical.

On Tuesday we learned that Regeneron's (REGN) cocktail for treating high-risk patients has proven to be highly effective in reducing hospitalizations and death. But will this drug ever see the light of day? Or will it get lost in the red tape, relegated to a government stockpile?

Let's check out the charts to see what investors may be thinking.

In this daily bar chart of REGN, below, we can see that prices have been in a downtrend since July. REGN is trading below the declining 50-day moving average line AND the declining 200-day moving average line.

The On-Balance-Volume (OBV) line has generally been on the defensive since June.

The 12-day price momentum study shows a low in late November and a higher low in February which gives us a bullish divergence when compared to prices making lower lows. This divergence could foreshadow higher prices ahead if trading volume increases.

In this weekly bar chart of REGN, below, we can see that prices have been in a downtrend for several months. REGN is trading below the declining 40-week moving average line.

The weekly OBV line has been declining from May of 2020 and tells me that sellers of REGN have been more aggressive for the past 10 months.

The Moving Average Convergence Divergence (MACD) oscillator is below the zero line but very close to making a cover shorts buy signal.

In this daily Point and Figure chart of REGN, below, we can see a potential upside price target in the $600 area. We can also see plenty of potential overhead resistance.

In this weekly Point and Figure chart of REGN, below, we can see a bearish downside price target of $324. Ouch.

Bottom line strategy: I have no special knowledge about Regeneron's cocktail for treating high-risk COVID patients but the charts are not particularly attractive at this point in time. I am in no rush to be a buyer.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals | Mad Money | Coronavirus

More from Investing

Is This the Time to Buy Costco?

Bruce Kamich
May 19, 2022 3:05 PM EDT

Buy a falling knife? No, but this one's intriguing.

Stay on Track While Interpreting the Dow Theory and CSX Corp.

Bruce Kamich
May 19, 2022 2:26 PM EDT

Some investors may be asking whether we're seeing another 'nail in the coffin' of the secular bull market as several transport names get downgraded. Let's not ... go off the rails.

TJX Cos. Is Ignoring the Market's Downdraft

Bruce Kamich
May 19, 2022 1:25 PM EDT

Does this strength have staying power?

These ETFs Will Meet You in the After-Hours Club

Mark Abssy
May 19, 2022 12:30 PM EDT

Let's check three funds that are set to buy the close and sell the open.

After Wednesday's Bloodbath, a Battle Is Brewing in the Market

James "Rev Shark" DePorre
May 19, 2022 11:56 AM EDT

We see traders hunting for an oversold bounce, while investors are dashing for the exits. Here's my take on the wild action so far -- and whether we're in a recession yet.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login